RT Journal Article
SR Electronic
T1 Pilot study of the FoxP3+ T lymphocyte count and its relationship with the Gensini score in patients with coronary heart disease and type 2 diabetes mellitus from a South American cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.08.23296720
DO 10.1101/2023.10.08.23296720
A1 Estévez Gómez, María Juliana
A1 Acevedo Peña, Diego Andrey
A1 Castillo Goyeneche, Silvia Fernanda
A1 Arias, Anderson Felipe
A1 Dulcey Sarmiento, Luis Andres
A1 Gomez, Jaime
A1 Hernandez, Carlos
A1 Theran Leon, Juan Sebastián
A1 Caltagirone, Raimondo
A1 Blanco, Edgar
A1 Ciliberti, María
YR 2023
UL http://medrxiv.org/content/early/2023/10/09/2023.10.08.23296720.abstract
AB INTRODUCTION One of the pathogenic links between type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD) is low-intensity chronic inflammation, which is limited by FoxP3+ regulatory T cells.MATERIALS AND METHODS A comparative, observational, single-center, single-stage study was carried out. The severity of atherosclerosis was assessed by calculating the Gensini score based on selective coronary angiography. The absolute and relative content of CD4+CD25 high FoxP3+ and CD4+CD25 low FoxP3+ T cells in the blood was evaluated by flow cytometry.RESULTS 57 patients with chronic ischemic heart disease were examined. Patients with a combination of CHF and T2DM are characterized by an increase in the relative and absolute content of FoxP3+CD25 lymphocytes in the peripheral blood and an increase in the intranuclear content of FoxP3 in them, which is more pronounced in patients with disease moderate. atherosclerosis (Gensini score 17 to 45 points).CONCLUSIONS This was the first Latin American study that managed to show the relationship between an increase in the content of low FoxP3+CD25 lymphocytes in the peripheral blood with atherosclerosis in patients with a combination of coronary artery disease and DM2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not recive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of the Hospital de los Andes approved during its 253rd meeting in 2015 the conduct of this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are conteined in the manuscript